Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications

Praneet Kumar, Gary S. Francis, W. H. Wilson Tang

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.

Original languageEnglish (US)
Pages (from-to)349-355
Number of pages7
JournalNature Reviews Cardiology
Issue number5
StatePublished - May 2009


Dive into the research topics of 'Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications'. Together they form a unique fingerprint.

Cite this